Chia Jie Tan

Chia Jie Tan

Auto-generated profile, based on publicly available information

Chia Jie Tan

Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
RCRaymond J. Chan
Raymond J. Chan
Louisa GordonLouisa Gordon
Louisa Gordon
CTChia Jie Tan
Chia Jie Tan
ACAlexandre Chan
Alexandre Chan
NBNatalie Bradford
Natalie Bradford
CMChristine Miaskowski
Christine Miaskowski

30 July 2019 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
ACAlexandre Chan
Alexandre Chan
DHDaniel Hertz
Daniel Hertz
MMManuel Morales
Manuel Morales
EAElizabeth J. Adams
Elizabeth J. Adams
SGSharon Gordon
Sharon Gordon
MLMaryam Lustberg
Maryam Lustberg

11 April 2018 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
ACAlexandre Chan
Alexandre Chan
EPEileen Poon
Eileen Poon
WGWei Lin Goh
Wei Lin Goh
YGYanxiang Gan
Yanxiang Gan
CTChia Jie Tan
Chia Jie Tan
MFMohamad Farid
Mohamad Farid

11 October 2022 in Cancer Medicine
Verified
Journal Article
Open access
ACAlexandre Chan
Alexandre Chan
ICIvy Cheng
Ivy Cheng
CWClaire Wang
Claire Wang
CTChia Jie Tan
Chia Jie Tan
YTYi Long Toh
Yi Long Toh
ITIan Tannock
Ian Tannock
Background: There is little information about cancer‐related cognitive impairment (CRCI) in adolescent and young adults (AYA, 15–39 years old) due to its rare incidence. Here, we present the pre‐treatment (before chemotherapy or radiotherapy) evaluation of cognitive function and ability of AYA with cancer (AYAC) in a multicentered cohort study.Methods: Newly diagnosed AYAC and age‐matched healthy controls (HC) were recruited between 2018 and 2021. The primary outcome was the comparison of pre‐treatment cognitive impairment defined as 2 standard deviations (SDs) below the HC on ≥1 cognitive test, or >1.5 SDs below on ≥2 tests using CANTAB® between AYAC and HC. Secondary outcomes included self‐perceived cognitive ability assessed by FACT‐Cog v3 and biomarkers (inflammatory cytokines and brain‐derived neurotrophic factor [BDNF]).Results: We recruited 74 AYAC (median age = 34) and 118 HC (median age = 32). On objective cognitive testing, we observed three times more AYAC patients performed poorly on at least 2 cognitive tests compared to HC (40.5% vs. 13.6%, p < 0.001). AYAC self‐perceived less degree of cognitive impairment than HC (p < 0.001). However, AYAC perceived a greater impact of cognitive changes on their quality of life compared to HC (p = 0.039). Elevated baseline inflammatory markers (IL‐2, IL‐4, IL‐6, IL‐8, IL‐10 and IFN‐γ) were observed among AYAC compared to HC, and baseline BDNF was lower in AYAC compared to HC. Interaction effects between cancer diagnosis and biomarkers were observed in predicting cognitive function.Conclusion: With the pre‐existence of CRCI and risk factors of neuroinflammation even prior to systemic therapy, AYAC should receive early rehabilitation to prevent further deterioration of cognitive function after initiation of systemic therapies. (ClinicalTrials.gov Identifier: NCT03476070).

22 May 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
Lisa HolleLisa Holle
Lisa Holle
TBTegan Bilse
Tegan Bilse
RARamatu Masud Alabelewe
Ramatu Masud Alabelewe
PKPolly E Kintzel
Polly E Kintzel
EKEsin Aysel Kandemir
Esin Aysel Kandemir
BGBarry R Goldspiel
Barry R Goldspiel
The Oncology Pharmacy Team (OPT), consisting of specialty-trained pharmacists and/or pharmacy technicians, is an integral component of the multidisciplinary healthcare team (MHT) involved with all aspects of cancer patient care. The OPT fosters quality patient care, safety, and local regulatory compliance. The International Society of Oncology Pharmacy Practitioners (ISOPP) developed this position statement to provide guidance on five key areas: 1) oncology pharmacy practice as a pharmacy specialty; 2) contributions to patient care; 3) oncology pharmacy practice management; 4) education and training; and 5) contributions to oncology research and quality initiatives to involve the OPT. This position statement advocates that: 1) the OPT be fully incorporated into the MHT to optimize patient care; 2) educational and healthcare institutions develop programs to continually educate OPT members; and 3) regulatory authorities develop certification programs to recognize the unique contributions of the OPT in cancer patient care.

4 April 2023 in Addiction
Verified
Journal Article
Closed access
CTChia Jie Tan
Chia Jie Tan
TSTaylor Shufelt
Taylor Shufelt
EBEmma Behan
Emma Behan
JCJunpen Chantara
Junpen Chantara
CKChanchanok Koomsri
Chanchanok Koomsri
TDTeerapon Dhippayom
Teerapon Dhippayom